Search results for " GIS."

showing 10 items of 151 documents

Safety of etanercept and methotrexate in patients with rheumatoid arthritis and hepatitis C virus infection: a multicenter randomized clinical trial.

2014

Objective.To evaluate the safety and efficacy of therapy with etanercept and methotrexate (MTX) in patients with active rheumatoid arthritis (RA) and mild hepatitis C virus (HCV) infection.Methods.In this prospective open study, 29 patients with active RA were randomly assigned to receive therapy with MTX alone, etanercept alone, or a combination of MTX and etanercept, and monitored up to 54 weeks. The primary endpoint was safety; secondary aims were efficacy as defined by the 44-joint Disease Activity Score (DAS44) and health assessment questionnaire (HAQ). Serum liver enzymes and HCV viral load were serially measured.Results.In the whole cohort, aspartate aminotransferase (AST) serum leve…

MaleSettore MED/16 - REUMATOLOGIATNF-α INHIBITORSHEALTH ASSESSMENT QUESTIONNAIREHepacivirusmedicine.disease_causeVirus ReplicationGastroenterologySeverity of Illness IndexReceptors Tumor Necrosis FactorEtanerceptEtanerceptArthritis RheumatoidDISEASE ACTIVITY SCORELiver Function TestsRheumatoidReceptorsImmunology and AllergyProspective StudiesGISEAbiologyAlanine TransaminaseHepatitis CMiddle AgedViral LoadHepatitis CTreatment OutcomeRheumatoid arthritisAntirheumatic AgentsCombinationDrug Therapy CombinationFemaleTRANSAMINASESViral loadmedicine.drugmusculoskeletal diseasesAdultmedicine.medical_specialtyHepatitis C virusImmunologyDrug TherapyRheumatologyInternal medicinemedicineHumansAspartate AminotransferasesAgedHepatitisbusiness.industryArthritisTNF-alpha INHIBITORS TRANSAMINASES GISEA DISEASE ACTIVITY SCORE HEALTH ASSESSMENT QUESTIONNAIREmedicine.diseaseRheumatologyMethotrexateAlanine transaminaseImmunoglobulin GImmunologybiology.proteinTumor Necrosis FactorbusinessThe Journal of rheumatology
researchProduct

Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept…

2012

Objective: To evaluate the risk of serious infections (SIs) in RA patients receiving anti-TNF therapy on the basis of the data included in the GISEA register. METHODS: The study involved 2769 adult patients with long-standing RA (mean age 53.2±13.4years; mean disease duration 9.0±8.3years) enrolled in the GISEA register, who had been treated for at least 6months with TNF inhibitors or had discontinued therapy due to SI: 837 (30%) treated with infliximab (IFN), 802 (29%) with adalimumab (ADA), and 1130 (41%) with etanercept (ETN). RESULTS: 176 patients had experienced at least one of the 226 Sis during the 9years of treatment with an anti-TNF agent, an overall incidence of 31.8/1000 patient-…

Malerheumatoid arthritisArthritisReceptors Tumor Necrosis FactorEtanerceptEtanerceptArthritis RheumatoidAdalimumab; Adult; Aged; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Antirheumatic Agents; Arthritis Rheumatoid; Etanercept; Female; Humans; Immunoglobulin G; Incidence; Infection; Infliximab; Male; Middle Aged; Receptors Tumor Necrosis Factor; Registries; Tumor Necrosis FactorsRheumatoidadalimumabMonoclonalReceptorsImmunology and AllergyRegistriesinfectionsHumanizedAnti-TNF agents; GISEA register; Infections; Predictive factorsIncidence (epidemiology)IncidenceAntibodies MonoclonalAnti-TNF agentsMiddle AgedRheumatoid arthritisAntirheumatic AgentsCohortTumor Necrosis FactorsFemaleInfectionPredictive factorsmedicine.druganti-TNF; serious infections; rheumatoid arthritisAdultmedicine.medical_specialtyanti-TNF therapy; infections; rheumatoid arthritis; adalimumab; etanercept; infliximabanti-TNF therapyserious infectionsImmunologyInfections rheumatoid arthritis anti-TNF therapyAntibodies Monoclonal HumanizedInfectionsAntibodiesInternal medicinemedicineAdalimumabHumansAgedGISEA registerbusiness.industryArthritisAdalimumabanti-TNFGISEA register; Infections; Anti-TNF agents; Predictive factors; Adalimumab; Adult; Aged; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Antirheumatic Agents; Arthritis Rheumatoid; Etanercept; Female; Humans; Immunoglobulin G; Incidence; Infection; Infliximab; Male; Middle Aged; Receptors Tumor Necrosis Factor; Registries; Tumor Necrosis Factorsmedicine.diseaseInfliximabInfliximabConcomitantImmunoglobulin GImmunologyTumor Necrosis Factor InhibitorsbusinessTumor Necrosis Factorinfliximabetanercept
researchProduct

www.climateofburundi.org

2010

Daily rainfall and air temperature data were collected by IGEBU. For a given station, the number of missing daily rainfall data, MRDm (days), was determined for each month of the recording period. The monthly rainfall depth, Pm (mm), and the monthly number of rainy days, NRDm (days),were determined for each month with a complete record of daily rainfall data. For a given month, Pm was obtained by summing the daily rainfall depth values and NRDm was obtained by counting the number of days of the month characterized by a daily rainfall depth greater than zero. The number of missing daily temperature data, MTDm (days), was also determined for each month of the recording period. The mean of the…

Meteorological Data of Burundi Igebu Ruyigi Bujumbura Gitega Karuzi Gisozi Nyamuswaga Ruvyironza Rwegura Kirundo Ngozi Muyinga Cankuzo Kinyinya Muriza Musasa MuyagaSettore AGR/08 - Idraulica Agraria E Sistemazioni Idraulico-Forestali
researchProduct

La mobilità dei turisti nelle destinazioni: metodi di rilevazione e di analisi. Il caso studio dei croceristi nella città di Palermo.

Mobilità dei turisti GPS analisi GIS percorsi effettivi sviluppo destinazioneSettore SECS-S/05 - Statistica Sociale
researchProduct

OPEN GEONET: WebGIS Open Source of a GNSS Permanent Network

2010

In Sicily, from 2005 to 2007, a research group at Dipartimento di Rappresentazione (DIRAP), University of Palermo, Italy, has realized a Global Navigation Satellite System (GNSS) Network Real Time Kinematic (NRTK), project inside the “National Interest Research Program” PRIN2005 entitled ”Reti di stazioni permanenti per impieghi di controllo ed emergenza” founded by Minister of Instruction, University and Scientific Research (MIUR). With the rapid development of Internet and Web, Web Geographical Information System became an important aspect of GIS study. WebGIS software allow the most efficient and low-cost way in dissemination and sharing of geographic information for public and specific …

OPEN SOURCE WEBGIS GIS CORSSettore ICAR/06 - Topografia E Cartografia
researchProduct

Numerical, dimensional or mixed progression disease to imatinib as prognostic factor in patients with metastatic GIST.

2017

11040 Background: The majority of GIST patients with advanced disease initially achieves disease control from imatinib treatment. Approximately 10% of patients progresses within 6 months of starting therapy (primary resistance) and also 50-60% of the responding patients develops progression disease within two years (secondary resistance). Progression disease (PD) can be numerical, dimensional or mixed. The known prognostic factors of risk stratification in local disease are tumor size, mitotic activity and anatomic site. In this retrospective analysis we explore several clinical factors affecting survival in metastatic setting. Methods: The population included in this large database of 128…

OncologyCancer Researchmedicine.medical_specialtyPrognostic factorGiSTbusiness.industryImatinibDiseaseDisease controlMetastatic gistOncologyInternal medicineAdvanced diseaseMedicineIn patientbusinessmedicine.drugJournal of Clinical Oncology
researchProduct

Second-line treatment in exon 11-mutated GIST patients: Imatinib dose escalation or sunitinib? Retrospective analysis of a multi-institutional experi…

2014

10515 Background: Data from metastatic GIST patients harbouring exon 11 mutation who received a second line treatment with sunitinib or imatinib dose escalation were retrospectively analysed to compare survival. Methods: 123 exon 11 mutated advanced GIST patients were included. All patients progressed on imatinib 400 mg/die and received, on discretion of physician, a second line treatment with either imatinib (800 mg/die) or sunitinib (50 mg/die 4 weeks on/2 weeks of or 37.5 mg/day continuous daily dose). The type of exon 11 mutation was recorded (deletion versus others) and correlated with survival and response according to RECIST or CHOI criteria Results: 79 patients (64%) received a seco…

OncologyCancer Researchmedicine.medical_specialtySecond line treatmentGiSTSunitinibbusiness.industryImatinibMetastatic gistSurgeryExonOncologyInternal medicineDose escalationmedicineRetrospective analysisbusinessneoplasmsmedicine.drugJournal of Clinical Oncology
researchProduct

Technical and economical feasibility of biomass use for power generation in Sicily

2012

Biomass can provide a reliable support for production ofbiofuels while contributing to sustainable management of natural resources. Many countries, including Italy, have introduced important incentive schemes to support the use of biomass for electricity, heat and transportation. This has raised considerable interest towards the use of biomass for energy generation purposes. Nonetheless, the design and installation ofbiomass-fuelled power plants present several critical issues, such as choice and availability of biomass, choice of technology, power plant localization and logistics. The case study tackled in this paper evaluates the economies originated by a 1MW el Organic Rankine Cycle (ORC…

Organic Rankine cycleEngineeringPower stationbusiness.industryEnvironmental engineeringEnvironmental economicsNatural resourceElectricity generationSustainable managementBiofuelBioenergyBiomass GIS ORCSettore ING-IND/10 - Fisica Tecnica IndustrialeElectricitybusinessInformation Systems
researchProduct

A narrative approach for organizational learning in a diverse organisation

2006

PurposeThis paper aims to construct an approach referred to as “the participatory narrative” for organizational learning in diverse organizations. The approach is grounded in an understanding of organizational learning as the process of social construction which is narratively mediated.Design/methodology/approachThe participatory narrative is constructed theoretically. Additionally, the approach and its potential use are illustrated by means of a practical example.FindingsIt is shown that the participatory narrative enables interplay between various perspectives of diverse people. It makes it possible to overcome the temporal and spatial limits of organisational learning situations and help…

Organizational Behavior and Human Resource ManagementKnowledge managementSocial Psychologybusiness.industryOrganizational cultureDevelopmentNarrative inquiryParticipatory GISOrganization developmentNarrative networkOrganizational learningNarrativeSociologyOrganizational theorybusinessJournal of Workplace Learning
researchProduct

Prognostic Role of Plasma PD-1, PD-L1, pan-BTN3As and BTN3A1 in Patients Affected by Metastatic Gastrointestinal Stromal Tumors: Can Immune Checkpoin…

2021

Gastrointestinal stromal tumors (GISTs) represent 1% of all primary gastrointestinal tumors. Immune surveillance is often overcome by cancer cells due to the activation of immunoregulatory molecules such as programmed death protein (PD-1) and its ligand PD-L1, and butyrophilin sub-family 3A/CD277 receptors (BTN3A). Because several studies demonstrated that tumor PD-1 and PD-L1 expression may have a prominent prognostic function, this investigation aimed to discover if soluble forms of these molecules may be useful in predicting survival of metastatic GIST (mGIST) patients. Through specific ad hoc developed ELISA assays not yet available on the market, the circulating PD-1, PD-L1, BTN3A1, an…

PD-L10301 basic medicineCancer ResearchStromal cellSettore MED/06 - Oncologia MedicaArticle03 medical and health sciencesExon0302 clinical medicineImmune systemButyrophilinPD-L1PD-1Medicineprognostic biomarkerReceptorRC254-282butyrophilinsbiologyGiSTbusiness.industrycirculating immune checkpointsNeoplasms. Tumors. Oncology. Including cancer and carcinogensBTN3A1Antitumor immune response BTN3A1 Butyrophilins Circulating immune checkpoints GIST PD‐1 PD‐L1 Prognostic biomarkerantitumor immune response030104 developmental biologyOncology030220 oncology & carcinogenesisCancer cellCancer researchbiology.proteinbusinessGISTCancers
researchProduct